Loading...
XPARAFME
Market cap60mUSD
Dec 23, Last price  
1.48EUR
1D
3.50%
1Q
-21.69%
IPO
-82.17%
Name

Affluent Medical SAS

Chart & Performance

D1W1MN
XPAR:AFME chart
P/E
—
P/S
47.42
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
19.02%
Rev. gr., 5y
95.37%
Revenues
1m
-8.59%
3,00043,0001,429,000824,0001,451,0001,339,0001,224,000
Net income
-16m
L+2.80%
-5,837,000-8,752,000-16,588,999-14,319,000-14,820,000-15,227,000-15,653,000
CFO
-12m
L+8.78%
0-10,842,000-12,187,000-8,936,000-12,364,000-11,081,000-12,054,000

Profile

Affluent Medical SA develops minimally invasive medical devices for the treatment of heart and vascular diseases in France. It develops Kardiozis technology for the treatment of abdominal aortic aneurysm; Kalios and Epygon implants to treat mitral insufficiency; and Artus implant, an implantable electro-mechanical artificial sphincter for the treatment of severe urinary incontinence in women and men. The company was founded in 2011 and is based in Aix-en-Provence, France.
URL
https://www.affluentmedical.com/
IPO date
Jun 14, 2021
Employees
59
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122017‑122016‑12
Income
Revenues
1,224
-8.59%
1,339
-7.72%
1,451
76.09%
Cost of revenue
14,290
7,738
7,750
Unusual Expense (Income)
NOPBT
(13,066)
(6,399)
(6,299)
NOPBT Margin
Operating Taxes
(1,357)
(173)
(437)
Tax Rate
NOPAT
(11,709)
(6,226)
(5,862)
Net income
(15,653)
2.80%
(15,227)
2.75%
(14,820)
3.50%
Dividends
Dividend yield
Proceeds from repurchase of equity
12,553
5,742
21,425
BB yield
-23.32%
-18.10%
-20.25%
Debt
Debt current
2,077
2,062
2,753
Long-term debt
16,036
16,760
18,248
Deferred revenue
55,433
Other long-term liabilities
114
112
(55,207)
Net debt
16,437
16,181
9,134
Cash flow
Cash from operating activities
(12,054)
(11,081)
(12,364)
CAPEX
(171)
(146)
(334)
Cash from investing activities
(184)
(146)
(160)
Cash from financing activities
11,316
2,401
18,281
FCF
(11,114)
(5,975)
(6,087)
Balance
Cash
1,658
2,580
11,410
Long term investments
18
61
457
Excess cash
1,615
2,574
11,794
Stockholders' equity
(54,580)
(49,884)
(37,043)
Invested Capital
103,300
98,488
98,387
ROIC
ROCE
EV
Common stock shares outstanding
29,092
18,887
18,592
Price
1.85
10.12%
1.68
-70.47%
5.69
 
Market cap
53,820
69.62%
31,729
-70.01%
105,788
 
EV
70,257
118,500
170,097
EBITDA
(10,653)
(4,051)
(3,967)
EV/EBITDA
Interest
393
1,080
3,055
Interest/NOPBT